| Factor Information | |
|---|---|
| Data ID | 2706 |
| Factor | PVR/SVR ratio |
| Description | The pulmonary vascular resistance/systemic vascular resistance ratio decreased significantly in VSD group, whereas there was a trend toward decrease in the ASD and PDA groups. |
| Biomarker | NA |
| Classification | E10 (physiological factor - other) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | The potential effect of sildenafil on pulmonary arterial hypertension related to CHD may be associated with shunt location. |
| p Value | 0.006 |
| Conclusion | The pulmonary vascular resistance/systemic vascular resistance ratio decreased significantly in VSD group, whereas there was a trend toward decrease in the ASD and PDA groups. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 484 |
| CHD Type | isolated CHD |
| CHD Subtype | ASD/VSD/PDA |
| Reference | |
|---|---|
| PMID | 21678455 |
| Year | 2011 |
| Title | The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease |
| Sample | ||
|---|---|---|
| Population | adults | |
| Source | 12-week, prospective, open label, multicenter trial | |
| Region | Beijing, China | |
| Method | 12-week, prospective, open label, multicenter trial | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | VSD (12 Weeks)(Treatment) | VSD (Baseline)(Control) |
| Number | 24 | 24 |
| Age | 26.58 ± 9.61 years | 26.58 ± 9.61 years |
| Gender (Male: Female) | 08:16:00.000 | 08:16:00.000 |
| Marker Level | 0.91 ± 0.40 | 1.48 ± 0.96 |
